11 / 80
CARDIOVASCULAR JOURNAL OF AFRICA • Volume 28, No 3, May/June 2017
AFRICA
145
is comparable with the study of Barrero and co-workers.
30
They
showed that creatinine and sodium clearance decreased after
ethanol application in rats.
The kidneys play a critical role in long-term control of blood
pressure. Reduction in renal sodium excretion or a rightward
shift in the pressure–natriuresis relationship results in persistent
hypertension, and NO plays an important role in this process by
regulating the renal response to changes in perfusion pressures.
Suprisingly, renal functional parameters were not affected by
NOS inhibition in our study.
Tolins
et al
.
31
revealed that renal and systemic vascular
resistance increased, and renal blood flow and sodium excretion
were decreased by NOS inhibition. Griffin
et al
.
32
showed
that Sprague-Dawley rats from Harlan, which exhibited the
expected hypertension, proteinuria and glomerular damage, and
those from Charles River, which showed a blunted increase in
blood pressure and a resistance to nephropathy, exhibited large
differences in susceptibility to nephropathy by L-NAME-induced
NOS inhibition over a period of four weeks. We used L-NNA
instead of L-NAME for NOS inhibition in order to obtain
earlier blood pressure increase, and we evaluated fluid balance,
C
Na
, GFR and %FENa but not proteinuria and morphological
parameters of renal damage over a period of 10 days.
Conclusion
Although it is a potent anti-oxidant and inceases NO production/
bioavailibilty, resveratrol was incapable of preventing the
development of hypertension or reversing the blood pressure
increase in L-NNA-induced hypertension models in our study.
We cannot generalise this finding, as resveratrol is not a good
candidate for the treatment of hypertension developed via the
NOS-inhibition pathway. We suggest that further studies are
needed to assess this hypothesis, with higher doses and/or longer
periods of time.
This work was supported by Research Fund of the Canakkale Onsekiz Mart
University; project number: 2010/069
References
1.
Hill C, Lateef AM, Engels K, Samsell L, Baylis C. Basal and stimulated
nitric oxide in control of kidney function in the aging rat.
Am J Physiol
1997;
272
:1747–1753.
2.
Linder L, Kiowski W, Buhler FR, Luscher TF. Indirect evidence for
release of endothelium-derived relaxing factor in human forearm circu-
lation
in vivo
. Blunted response in essential hypertension.
Circulation
1990;
81
: 1762–1767.
3.
Savio M, Coppa T, Bianchi L, Vannini V, Maga G, Forti L,
et al
. The
resveratrol analogue 4,4’-dihydroxy-trans-stilbene inhibits cell prolifera-
tion with higher efficiency but different mechanism from resveratrol.
Int
J Biochem Cell Biol
2009;
41
: 2493–2502.
4.
Hsieh TC. Antiproliferative effects of resveratrol and the mediating role
of resveratrol targeting protein NQO2 in androgen receptor-positive,
hormone-non-responsive CWR22Rv1 cells.
Anticancer Res
2009;
29
:
3011–3017.
5.
Csiszar A, Labinskyy N, Olson S, Pinto JT, Gupte S, Wu JM,
et al
.
Resveratrol prevents monocrotaline-induced pulmonary hypertension
in rats.
Hypertension
2009;
54
: 668–675.
6.
Müller C, Ullmann K, Wilkens A, Winterhalter P, Toyokuni S, Steinberg
P. Potent antioxidative activity of Vineatrol30 grapevine-shoot extract.
Biosci Biotechnol Biochem
2009;
73
: 1831–1836.
7.
Kao CL, Tai LK, Chiou SH, Chen YJ, Lee KH, Chou SJ,
et al
.
Resveratrol promotes osteogenic differentiation and protects against
dexamethasone damage in murine induced pluripotent stem cells.
Stem
Cells Dev
2010;
19
: 247–258.
8.
Oktar S, Ilhan S, Aksulu HE. Clonidine prevents development of hyper-
tension in N (omega)-nitro-L-arginine-treated rats.
Anadolu Kardiyol
Derg
2008;
8
: 104–110.
9.
Vapaatalo H, Mervaala E, Nurminen ML. Role of endothelium and
nitric oxide in experimental hypertension.
Physiol Res
2000;
49
: 1–10.
10. Harrison DG, Gongora MC, Guzik TJ, Widder J. Oxidative stress and
hypertension.
J Am Soc Hypertens
2007;
1
: 30–44.
11. Wilcox CS, Welch WJ. Oxidative stress: cause or consequence of hyper-
tension.
Exp Biol Med
(Maywood) 2001;
226
: 619–220.
12. Silan C, Uzun O, Ustundag Comunoglu N, Gokcen S, Bedirhan S,
Cengiz M, Gentamicin induced nephrotoxicity in rats ameroliorated and
healing effects of Resveratrol.
Biol Pharm Bull
2007;
30
: 79–83.
13. Ozkan OV, Yuzbasioglu MF, Ciralik H, Kurutas EB, Yonden Z,
Aydin M,
et al
. Resveratrol, a natural antioxidant, attenuates intesti-
nal ischemia/reperfusion injury in rats.
Tohoku J Exp Med
2009;
218
:
251–258.
14. Silan C. The effects of chronic resveratrol treatment on vascular respon-
siveness of streptozotocin-induced diabetic rats.
Biol Pharm Bull
2008;
31
: 897–902.
15. Sadruddin S, Arora R. Resveratrol: biologic and therapeutic implica-
tions.
J Cardiometab Syndr
2009;
4
: 102–106.
16. Wong RH, Howe PR, Buckley JD, Coates AM, Kunz I, Berry NM.
Acute resveratrol supplementation improves flow-mediated dilatation in
overweight/obese individuals with mildly elevated blood pressure.
Nutr
Metab Cardiovasc Dis
2011;
21
: 851–856.
17. Gojkovic-Bukarica L, Novakovic A, Kanjuh V, Bumbasirevic M, Lesic
A, Heinle H. A role of ion channels in the endothelium-independent
relaxation of rat mesenteric artery induced by resveratrol.
J Pharmacol
Sci
2008;
108
: 124–130.
18. Zhang HY, Xu CQ, Li HZ, Li BX, Zhang YQ, Zhang YN. Effects of
resveratrol on isolated thoracic aorta rings of rats.
Zhongguo Zhong Yao
Za Zhi
2005;
30
: 1283–1286.
19. Leblais V, Krisa S, Valls J, Courtois A, Abdelouhab S, Vila AM,
et al
.
Relaxation induced by red wine polyphenolic compounds in rat pulmo-
nary arteries: lack of inhibition by NO-synthase inhibitor.
Fundam
ClinPharmacol
2008;
22
: 25–35.
20. Deniz E, Sahna E, Aksulu HE. Nitric oxide synthase inhibition in rats:
melatonin reduces blood pressure and ischemia/reperfusion-induced
infarct size.
Scand Cardiovasc J
2006;
40
(4): 248–252.
21. Nabha L, Garbern JC, Buller CL, Charpie JR. Vascular oxidative stress
precedes high blood pressure in spontaneously hypertensive rats.
Clin
Exp Hypertens
2005;
27
: 71–82.
22. Hu L, Zhang Y, Lim PS, Miao Y, Tan C, McKenzie KU,
et al
. Apocynin
but not L-arginine prevents and reverses dexamethasone-induced hyper-
tension in the rat.
Am J Hypertens
2006;
19
: 413–418.
23. Schnackenberg CG, Welch WJ, Wilcox CS. Normalization of blood
pressure and renal vascular resistance in SHR with a membrane-perme-
able superoxide dismutase mimetic: role of nitric oxide.
Hypertension
1998;
32
: 59–64.
24. Bhatt SR, Lokhandwala MF, Banday AA. Resveratrol prevents endothe-
lial nitric oxide synthase uncoupling and attenuates development of
hypertension in spontaneously hypertensive rats.
Eur J Pharmacol
2011;
30
: 258–264.
25. Gordish KL, Beierwaltes WH. Resveratrol induces acute endothelium-